PDCD1 and hepatocellular carcinoma: However, a regorafenib plus anti-PD-1 (pembrolizumab) regimen is currently under investigation in a global phase 3 trial, in comparison with transarterial chemoembolization or radioembolization, among patients with intermediate-stage HCC (REPLACE, NCT04777851).